Core Insights - Aptevo Therapeutics reported significant clinical progress and financial results for 2025, highlighting the potential of mipletamig in enhancing frontline AML treatment alongside standard therapies [2][3][4] Clinical Performance - Mipletamig demonstrated an 86% clinical benefit rate in combination therapy for frontline AML patients, with a 79% complete response (CR) or complete response with incomplete blood count recovery (CRi) rate, compared to 66% for standard care [5][7] - The treatment showed a 61% complete remission rate, significantly higher than the 37% observed with standard therapies [5] - No cytokine release syndrome was reported in patients treated with mipletamig, indicating a favorable safety profile [7][8] Pipeline Expansion - The company expanded its CD3 pipeline by introducing three new multispecific candidates, including its first two trispecific drug candidates, enhancing its ability to target a broader range of tumor types [4][9] - The new candidates leverage the proprietary CRIS7-derived CD3 binding domain, aimed at promoting targeted T-cell activation while minimizing systemic overstimulation [10] Financial Overview - Aptevo ended 2025 with $21.6 million in cash and cash equivalents, an increase from $8.7 million in 2024, supporting operations into the fourth quarter of 2026 [11][14] - Research and development expenses rose to $14.5 million in 2025 from $14.4 million in 2024, primarily due to increased costs associated with mipletamig [14] - General and administrative expenses increased to $11.8 million in 2025, up from $10.2 million in 2024, driven by higher employee and consulting costs [15] Capital Strategy - In 2026, Aptevo established a $60 million equity line facility to enhance financial flexibility and support ongoing operations, with the potential to extend its capital runway into 2029 if fully utilized [4][12]

Core Insights - 100% of patients in Cohorts 1-3 remain free of cytokine release syndrome, indicating a strong safety profile for the CD3 design used in the study [1] - The study evaluates mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia patients unfit for intensive chemotherapy [1] - Preliminary results were presented at the American Society of Hematology Annual Meeting, highlighting the potential of the ADAPTIR™ and ADAPTIR-FLEX™ platform technologies developed by the company [1] Company Summary - Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics [1] - The company utilizes proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies in its research and development efforts [1] Industry Context - The ongoing Phase 1b/2 RAINIER study is significant for the treatment of acute myeloid leukemia, particularly for patients who cannot undergo intensive chemotherapy [1] - The combination of mipletamig with standard treatments like azacitidine and venetoclax represents a potential advancement in the therapeutic options available for AML [1]